Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance.
about
Helicobacter pylori infection in Japan'Rescue' therapies for the management of Helicobacter pylori infection.Population-based strategies for Helicobacter pylori-associated disease management: a Japanese perspective.Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy.Immunological response to parenteral vaccination with recombinant hepatitis B virus surface antigen virus-like particles expressing Helicobacter pylori KatA epitopes in a murine H. pylori challenge model.Therapy of Helicobacter pylori.Molecular biology methods for the characterization of Helicobacter pylori infections and their diagnosis.Eradication of Helicobacter pylori: recent advances in treatment.Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005.Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics.Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study.Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pylori.A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication).Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype.Systematic review and meta-analysis: triple therapy combining a proton-pump inhibitor, amoxicillin and metronidazole for Helicobacter pylori first-line treatment.Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan.Effect of dosing schemes of amoxicillin on eradication rates of Helicobacter pylori with amoxicillin-based triple therapy.Four-times-daily Dosing of Rabeprazole with Sitafloxacin, High-Dose Amoxicillin, or Both for Metronidazole-Resistant Infection with Helicobacter pylori in Japan.High Helicobacter pylori cure rate with sitafloxacin-based triple therapy.Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion.Efficacy of 10-day Sitafloxacin-Containing Third-Line Rescue Therapies for Helicobacter pylori Strains Containing the gyrA Mutation.Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori.High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection.A new eradication resistance index as a predictor of metronidazole-containing second-line treatment of Helicobacter pylori.Modified allele-specific primer-polymerase chain reaction method for analysis of susceptibility of Helicobacter pylori strains to clarithromycin.Trends of second-line eradication therapy for Helicobacter pylori in Japan: a multicenter study in the Tokyo metropolitan area.Nutrition status and Helicobacter pylori infection in patients receiving hemodialysis.
P2860
Q27010197-1C676013-17D6-4103-9812-18DBFFB2FA7DQ33371187-0EA179EE-5492-4E26-845A-B7F33345E417Q33960344-FA6481F5-46F0-41D1-B1E7-1E3A86394523Q35056670-B3F312AB-4893-4F54-BA49-813792AF5320Q35739112-5CEFF4C1-9FC3-4782-9124-D9FCDA147793Q35878337-7ED61C65-E9CF-4660-A1BB-1316729D3B4AQ36028541-65A77853-A9C7-41AD-BE9B-FFD78A37EBCBQ36191284-07ED820C-473F-4743-851E-30A5965BE284Q36314577-3EE57786-DE1B-4926-89D0-7E8AA940C089Q36979297-E21BDCBD-302F-4D83-AD81-782C1A7BDD6AQ37045762-0E5A98ED-56B9-415D-9FE7-7161F4D53298Q37393730-670CD872-23DA-4F66-91B3-DECF351381EFQ38093864-83F4DE2D-3B31-4EAC-A144-23932A287261Q38219028-95989E17-7E89-454F-8963-0754E76A4043Q38876344-30E25F8B-8D8F-4B2A-87A4-C64B86E1D1DDQ39014376-CBFA4B78-A7F7-4344-A794-9F7718536E6CQ39014381-77BF34A3-150C-4BF7-888B-8ED3E403B760Q39496571-6594CC7C-C588-4CED-95AE-EEE997486D85Q39496596-CD6CD5BE-244A-47CF-8B8F-F6C4C9A13598Q39496607-221957A1-3F92-4429-9928-BE28AA7EF51EQ40892650-A3FFFA46-6AEA-4BC4-A3A2-C0588E1687EEQ44371256-A3A55235-7DBA-4CE6-83E6-D4BF70D7EB4DQ44505171-A1A4D769-3800-447B-B0A0-A17B2D4C3EE1Q46823725-7744509F-D3FE-4C1B-BBBF-8C0705039DD5Q46967724-07B785C2-535B-42D6-8C83-61346FC01393Q51804069-9203E3BD-578E-455E-BCE4-C3AC0601ECF6Q55092506-D93D7A47-F835-456A-85F3-ADAAC99B534A
P2860
Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Efficacy of triple therapy com ...... e of metronidazole resistance.
@en
Efficacy of triple therapy com ...... e of metronidazole resistance.
@nl
type
label
Efficacy of triple therapy com ...... e of metronidazole resistance.
@en
Efficacy of triple therapy com ...... e of metronidazole resistance.
@nl
prefLabel
Efficacy of triple therapy com ...... e of metronidazole resistance.
@en
Efficacy of triple therapy com ...... e of metronidazole resistance.
@nl
P2093
P2860
P1476
Efficacy of triple therapy com ...... e of metronidazole resistance.
@en
P2093
K Murakami
P2860
P304
P356
10.1046/J.1365-2036.2003.01401.X
P407
P577
2003-01-01T00:00:00Z